SN-28 | 1000410-34-3

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: SN-28
• 英文别名: 6,7-didehydro-17-methyl-quinolino[2',3':6,7]morphinan-3-ol；(1S,14R,15R)-25-methyl-4,25-diazahexacyclo[13.7.3.01,14.03,12.05,10.017,22]pentacosa-3,5,7,9,11,17(22),18,20-octaen-20-ol
• CAS: 1000410-34-3
• 化学式: C₂₄H₂₄N₂O
• 分子量: 356.467
• InChiKey: HDRKKGULQPRYBL-TUACAJSNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  SN-28 在 盐酸 作用下， 以 甲醇 、 氯仿 为溶剂， 以80%的产率得到6,7-didehydro-17-methyl-quinolino[2',3':6,7]morphinan-3-ol hydrochloride
  参考文献：
  名称：

  Synthesis of quinolinomorphinan-4-ol derivatives as δ opioid receptor agonists

  摘要：

  The previously reported morphinan derivative SN-28 showed high selectivity and agonist activity for the delta opioid receptor. In the course of examining the structure-activity relationship of SN-28 derivatives, the derivatives with the 4-hydroxy group (SN-24, 26, 27) showed higher selectivities for the 8 receptor over the mu receptor than the corresponding SN-28 derivatives with the 3-hydroxy group (SN-11, 23, 28). Derivatives with the 4-hydroxy group showed potent agonist activities for the 5 receptor in the [S-35]GTPyS binding assay. Although the 17-cyclopropylmethyl derivative (SN-11) with a 3-hydroxy group showed the lowest selectivity for the delta receptor among the morphinan derivatives, the agonist activity toward the delta receptor was the most potent for candidates with the 3-hydroxy group. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.047
• 作为产物：
  描述：

  (1'R,9'R,10'S)-17'-(cyclopropylmethyl)-4'-methoxyspiro[1,3-dioxolane-2,13'-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene]-10'-ol 在 吡啶 、 盐酸 、 platinum(IV) oxide 、 lithium aluminium tetrahydride 、 氯化亚砜 、 甲烷磺酸 、 氢气 、 三溴化硼 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 1,1,2,2-四氯乙烷 为溶剂， 反应 45.0h， 生成 SN-28
  参考文献：
  名称：

  Synthesis of quinolinomorphinan-4-ol derivatives as δ opioid receptor agonists

  摘要：

  The previously reported morphinan derivative SN-28 showed high selectivity and agonist activity for the delta opioid receptor. In the course of examining the structure-activity relationship of SN-28 derivatives, the derivatives with the 4-hydroxy group (SN-24, 26, 27) showed higher selectivities for the 8 receptor over the mu receptor than the corresponding SN-28 derivatives with the 3-hydroxy group (SN-11, 23, 28). Derivatives with the 4-hydroxy group showed potent agonist activities for the 5 receptor in the [S-35]GTPyS binding assay. Although the 17-cyclopropylmethyl derivative (SN-11) with a 3-hydroxy group showed the lowest selectivity for the delta receptor among the morphinan derivatives, the agonist activity toward the delta receptor was the most potent for candidates with the 3-hydroxy group. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.047

文献信息

• Design and synthesis of novel delta opioid receptor agonists and their pharmacologies
  作者：Hiroshi Nagase、Yumiko Osa、Toru Nemoto、Hideaki Fujii、Masayuki Imai、Takashi Nakamura、Toshiyuki Kanemasa、Akira Kato、Hiroaki Gouda、Shuichi Hirono

  DOI：10.1016/j.bmcl.2009.03.099

  日期：2009.5

  We re-examined the accessory site of the 4,5-epoxymorphinan skeleton by CAMDAS conformational analysis in an effort to deign novel delta opioid receptor antagonists. We synthesized three novel compounds (SN-11, 23 and 28) with a 10-methylene bridge and without a 4,5-epoxy ring. Among them, compounds SN-23 (17-isobutyl derivative) and SN-28 (17-methyl derivative) showed very strong agonist activity (over 10 times more than TAN-67). SN-28 also showed high delta selectivity. The delta agonist activity of SN-23 was weaker than that of SN-28, but in terms of the delta selectivity, SN-23 was higher than that of SN-28. These unexpected results indicated that the 4,5-epoxy ring, but not the 10-methylene bridge, was an accessory site in delta opioid receptor agonists. (C) 2009 Elsevier Ltd. All rights reserved.
• US20140343015A1
  申请人：——

  公开号：US20140343015A1

  公开（公告）日：2014-11-20
• MORPHINAN DERIVATIVE
  申请人：THE KITASATO INSTITUTE

  公开号：US20160122349A1

  公开（公告）日：2016-05-05

  The present invention relates to a morphinan derivative represented by the following general formula (I), wherein R 1 represents hydrogen, C 1-6 alkyl, C 6-10 aryl, etc., R 2 and R 3 , which are the same or different, represent hydrogen, hydroxy, etc., R 4 and R 5 represent hydrogen, C 1-6 alkyl, etc., R 6 represents hydrogen, hydroxy, C 1-6 alkyl, etc., X represents O or CH 2 , Y represents C═O, C(═O)O, etc., and m and n, which are the same or different, represent an integer of 0 to 2 (m and n are not 0 at the same time), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as an analgesic, antianxiety drug, etc. containing the same as an active ingredient.
• US8952030B2
  申请人：——

  公开号：US8952030B2

  公开（公告）日：2015-02-10
• US9624223B2
  申请人：——

  公开号：US9624223B2

  公开（公告）日：2017-04-18